Recombinetics
From Wikipedia, the free encyclopedia
Recombinetics is a St. Paul, Minnesota-based bio-engineering company.[1] The company was founded in 2008, and has since raised $31 million from private investors. Mark Platt is the CEO.[2]
In November 2024, Recombinetics filed for Chapter 11 bankruptcy protection. The company has plans to be acquired by Trans Ova Genetics for $4.1 million.[3]
